Technical Analysis for ZOM - Zomedica Pharmaceuticals Corp

Grade Last Price % Change Price Change
grade D 1.07 -13.71% -0.1700
ZOM closed down 13.71 percent on Friday, January 25, 2019, on approximately normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent N/A N/A Down
See historical ZOM trend table...

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
Hot IPO Pullback Bullish Swing Setup 0.00%
Inside Day Range Contraction 0.00%
Hot IPO Pullback Bullish Swing Setup -13.71%
New 52 Week Low Weakness -13.71%
New 52 Week Closing Low Bearish -13.01%
Hot IPO Pullback Bullish Swing Setup -13.01%
Doji - Bullish? Reversal -13.01%
New 52 Week Low Weakness -13.01%
Down 3 Days in a Row Weakness -13.01%

Older signals for ZOM ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Zomedica Pharmaceuticals Corp., a development stage veterinary diagnostic and pharmaceutical company, engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. The company's lead drug product candidate is ZM-012, a tablet formulation of metronidazole targeting the treatment of acute diarrhea in dogs. It is also developing ZM-007, an oral suspension formulation of metronidazole for the treatment of acute diarrhea in small dog breeds and puppies; ZM-006, a transdermal gel formulation of methimazole targeting hyperthyroidism in cats; and ZM-011, a transdermal gel formulation of fluoxetine for the treatment of feline behavioral disorders, such as inappropriate urination. The company has a collaboration agreement with Celsee Diagnostics, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and with Seraph Biosciences, Inc. for development and commercialization of novel pathogen detection system, as well as a development agreement with IncellDx, Inc. Zomedica Pharmaceuticals Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan.
Health RTT Cancer Pharmaceuticals Drugs Chemical Substances Hyperthyroidism
Is ZOM a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 1 bearish and 4 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Indicators
Indicator Value
52 Week High 2.25
52 Week Low 0.8166
Average Volume 46,131
200-Day Moving Average 0.0
50-Day Moving Average 0.0
20-Day Moving Average 0.0
10-Day Moving Average 1.663
Average True Range 0.0
ADX 0.0
+DI 0.0
-DI 0.0
Chandelier Exit (Long, 3 ATRs ) N/A
Chandelier Exit (Short, 3 ATRs ) N/A
Upper Bollinger Band 0.0
Lower Bollinger Band 0.0
Percent B (%b) 0.0
BandWidth 0.0
MACD Line -0.0501
MACD Signal Line -0.01
MACD Histogram -0.0401
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.2050
Resistance 3 (R3) 1.2133 1.1767 1.1825
Resistance 2 (R2) 1.1767 1.1423 1.1725 1.1750
Resistance 1 (R1) 1.1233 1.1210 1.1050 1.1150 1.1675
Pivot Point 1.0867 1.0867 1.0775 1.0825 1.0867
Support 1 (S1) 1.0333 1.0523 1.0150 1.0250 0.9725
Support 2 (S2) 0.9967 1.0310 0.9925 0.9650
Support 3 (S3) 0.9433 0.9967 0.9575
Support 4 (S4) 0.9350